Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients

Inclusion Criteria: * Histologic diagnosis of squamous cell carcinoma of esophagus. Preoperative stage Ⅱ-Ⅲ by endoscopic ultrasound, CT of the chest and abdomen,and esophagogram. * Age ranges from 18 to 70 years. * Patients must not have received any prior anticancer therapy. * Performance status of 0 to 1 * Estimated life expectancy of at least 6 months. * Tumor can be measured according to RECIST criteria * Signed informed consent document on file. * Females with childbearing potential must have a negative serum pregnancy * Adequate organ function including the following: Bone marrow: Absolute neutrophil count (ANC) greater than or equal 1.5×109/L Platelets greater than or equal 80×109/L Haemoglobin greater than or equal 80g/L Hepatic: total bilirubin less than or equal to 1.5 times upper limit of normal (ULN), Alanine transaminase (ALT) and aspartate transaminase (AST) less than or equal to 2.5 times ULN Renal: calculated creatinine clearance rate≥60ml/min. test within 7 days prior to study enrollment. Exclusion Criteria: * Carcinoma at the upper part of esophagus * Histologic diagnosis of adenocarcinoma of esophagus. * Prior treatment for esophageal cancer. * Active infection. * Pregnant or breast feeding. * History of significant neurological or mental disorder, including seizures or dementia. * Prior invasive malignancy in 5 years (except for carcinoma in situ).